Please enable JavaScript or talk to your local administrator to get JavaScript enabled.

Project

Efficacy of immunotherapy in the first and second line treatment of metastatic bladder cancer

Funder: German Research Foundation

Funding period
0
Funding amount
Abstract
Since the implementation of checkpoint inhibitors in the sequence therapy of metastatic bladder cancer just a few years ago, a new era for one of the most common tumor entities in Europe has begun. However, only a few studies on checkpoint therapy are available today. Most of these studies are phase-II, to some extent with small patient populations. This situation may cause a distortion in the estimated effects of immunotherapy or worst a distortion of the study results. Aim of this research project is the preparation of a Cochrane Review on immunotherapy for metastatic bladder cancer, which summarizes the current state of knowledge of this new therapy. Cochrane Reviews are internationally recognized as a quality standard in evidence-based medicine. According to the Cochrane guidelines, a systematic literature review, a systematic data extraction as well as data evaluation in terms of a meta-analysis will be carried out at the highest level of methodological quality. The scientific benefit of this Cochrane Review is a summary and evaluation of the currently available evidence. Compared to many individual studies, this evidence synthesis and -assessment helps to improve the trustworthiness of the estimated effects for the benefits or harms of an immunotherapy for metastatic bladder cancer. As a clinical benefit, these results will help to better quantify the effects and impairments of immunotherapy on affected patients. Due to the implementation of this Cochrane Review into clinical routine (e.g. guidelines), patient’s treatment should be improved.
Similar projects All >
Sorted by: Start Date
Project list item
Targeting regulatory B cells (Bregs) to improve anti-bladder cancer immunity

Bladder Cancer Advocacy Network to Burles Avner Johnson, David McConkey

USD 50,000
2020 - 2021
Project list item
Implication of neutrophil extracellular traps in the efficacy of bladder-sparing therapy in muscle invasive bladder cancer

Canadian Institutes of Health Research to Wassim Kassouf, Jonathan David Spicer, Ciriaco A. Piccirillo

USD 138,878
2020 - 2025
Project list item
Dissecting myeloid cell-mediated resistance to immune checkpoint blockade in bladder cancer

National Cancer Institute to NINA BHARDWAJ, JUN ZHU, MATTHEW GALSKY

USD 703,400
2020 - 2025
Project list item
CD40 agonism for the treatment of bladder cancer

National Cancer Institute to CHRISTOPHER STUART GARRIS

USD 64,554
2020 - 2023
Project list item
Roles of epigenetic regulators in bladder cancer progression

University of California - Cancer Research Coordinating Committee to Zhu Wang

USD 74,960
2020 - 2020

System

Categories
  • FOR (ANZSRC)

    1112 Oncology and Carcinogenesis

  • RCDC

    Cancer

  • RCDC

    Immunization

  • RCDC

    Urologic Diseases

  • RCDC

    Vaccine Related

  • HRCS HC

    Cancer

  • HRCS RAC

    6.1 Pharmaceuticals

  • Health Research Areas

    Clinical

  • Broad Research Areas

    Clinical Medicine and Science